Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.
复制标题
DOI：
10.1586/14737167.8.2.165
复制
发表时间：
2008-04-01
影响因子：
2.3
通讯作者：
Grosse, Scott D
中科院分区：
文献类型：
--
作者：
Grosse, Scott D
成本效益分析，特别是在美国，通常使用每生命年或经质量调整的生命年增加5万美元的数字作为评估干预措施成本效益的门槛。这种做法的历史定义不明确，尽管它与20世纪80年代以来的终末期肾脏疾病肾脏透析成本效益文献有关。使用50,000美元作为评估干预措施成本效益的基准最早出现在1992年，并在1996年之后得到广泛使用。5万美元这个数字的吸引力似乎在于一个整数的便利性，而不是肾脏透析的价值。我们需要的不是武断的门槛，而是对医疗资源的支付意愿和机会成本的估计。
Cost-effectiveness analyses, particularly in the USA, commonly use a figure of $50,000 per life-year or quality-adjusted life-year gained as a threshold for assessing the cost-effectiveness of an intervention. The history of this practice is ill defined, although it has been linked to the end-stage renal disease kidney dialysis cost-effectiveness literature from the 1980s. The use of $50,000 as a benchmark for assessing the cost-effectiveness of an intervention first emerged in 1992 and became widely used after 1996. The appeal of the $50,000 figure appears to lie in the convenience of a round number rather than in the value of renal dialysis. Rather than arbitrary thresholds, estimates of willingness to pay and the opportunity cost of healthcare resources are needed.